tailieunhanh - A retrospective study of alectinib versus ceritinib in patients with advanced non– small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resistance. Comparison of using second-generation ALK inhibitors in this setting remains lacking. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN